TELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)
TELA Bio (NASDAQ:TELA) Full Year 2023 Results
Key Financial Results
Revenue: US$58.5m (up 41% from FY 2022).
Net loss: US$46.7m (loss widened by 5.3% from FY 2022).
US$2.04 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
TELA Bio Earnings Insights
In the last 12 months, the only revenue segment was Surgical & Medical Equipment contributing US$58.5m. The largest operating expense was Sales & Marketing costs, amounting to US$59.7m (68% of total expenses). Explore how TELA's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are up 7.5% from a week ago.
Risk Analysis
Be aware that TELA Bio is showing 2 warning signs in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
